Clinical trials: Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma
This Phase I study will test the safety and anti-myeloma activity of ascending doses of Descartes-11 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.
- Trial name
- NCT03994705
- Testing
- Descartes-11, Fludarabine, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Cartesian Therapeutics
Relapsed or Refractory Multiple Myeloma
Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma
A study evaluating two new formulations of oprozomib plus pomalidomide and dexamethasone in participants with relapsed refractory multiple myeloma.
- Trial name
- INTREPID-1 (NCT02939183)
- Testing
- Immediate Release (IR) Formulation, Gastro-Retentive (GR) Formulation, Dexamethasone
- Where
- 20 sites in United States, Australia and 2 more
- Volunteers
- 61 people
- Sponsor
- Amgen
Myeloma Multiple, Myeloma
Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients
The purpose of this study is to determine the efficacy and safety of investigational combination therapy of Selinexor, Clarithromycin, Pomalidomide and Dexamethasone (ClaSPd) for patients with relapsed/refractory multiple…
- Conditions
- Myeloma Multiple, Myeloma, Refractory Multiple Myeloma
- Trial name
- ClaSPd (NCT04843579)
- Testing
- Selinexor, Clarithromycin, Pomalidomide
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Weill Medical College of Cornell University
Multiple Myeloma
APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma
The purpose of this study is to test the safety and efficacy of AUTO2, a CAR T Cell Treatment Targeting BCMA and TACI, in Patients with Relapsed or Refractory Multiple Myeloma.
- Trial name
- APRIL (NCT03287804)
- Testing
- AUTO2
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 12 people
- Sponsor
- Autolus Limited
Multiple Myeloma
Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma
The primary objective of this study is to determine the safety profile, tolerability, and maximum tolerated dose of ixazomib citrate (MLN9708) when taken orally on a weekly dosing schedule by patients with relapsed and refractory…
- Trial name
- NCT00963820
- Testing
- Ixazomib citrate
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Multiple Myeloma
A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Multiple myeloma (MM) is a neoplastic plasma cell disorder that is characterized by osteolytic bone lesions, anemia, hypercalcemia and renal failure.
- Trial name
- NCT04177823
- Testing
- Belantamab mafodotin
- Where
- China
- Volunteers
- 6 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody
Multiple myeloma (MM) is an incurable malignancy and accounts for 1 percentage (%) of all cancers and for 10% of all hematologic malignancies.
- Trial name
- NCT03525678
- Testing
- Belantamab mafodotin frozen liquid, Belantamab mafodotin lyophilized powder
- Where
- 59 sites in United States, Australia and 6 more
- Volunteers
- 221 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US
The purpose of the study is to understand how well elranatamab (PF-06863135) may be used for relapsed refractory multiple myeloma (RRMM).
- Trial name
- NCT06504524
- Testing
- Elranatamab, Standard of Care
- Where
- 2 sites in United States, Germany
- Volunteers
- 633 people
- Sponsor
- Pfizer
Multiple Myeloma, Acute Myeloid Leukemia
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
Evaluate the safety and tolerability of AMG 397. Estimate the maximum tolerated doses (MTDs) and/or biologically active doses.
- Conditions
- Multiple Myeloma, Acute Myeloid Leukemia, Non-Hodgkins Lymphoma, Myelodysplastic Syndrome
- Trial name
- NCT03465540
- Testing
- AMG 397, Dexamethasone, Azacitidine
- Where
- 21 sites in United States, Australia and 4 more
- Volunteers
- 24 people
- Sponsor
- Amgen